# Tirzepatide vs Dulaglutide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide

Last updated: 2026-10-06

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Tirzepatide vs Dulaglutide

Compared side by side

# Tirzepatide vs dulaglutide: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Dulaglutide activates one receptor, GLP-1; tirzepatide activates GLP-1 and GIP. Both are weekly shots with half-lives of about 5 days, and both are FDA-approved for type 2 diabetes, dulaglutide as Trulicity and tirzepatide as Mounjaro; only tirzepatide is approved for weight management, as Zepbound. Dulaglutide’s effect on weight is modest, about 1 to 5 kg on average in its diabetes trials, and tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1).

## Side by side

| Compared | [Tirzepatide](https://pepvault.app/peptides/tirzepatide) | [Dulaglutide](https://pepvault.app/peptides/dulaglutide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | Trulicity, LY2189265, Dula |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | FDA label: 0.75–4.5 mg, starting dose 0.75 mg. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~5 days (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Tirzepatide

- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course

[Every card for tirzepatide, with its sources](https://pepvault.app/peptides/tirzepatide#weeks)

### Dulaglutide

- Day 1–28 · 0.75 mg The 0.75 mg start
- Day 29–364 · 1.5 mg 1.5 mg, the dose of its heart trial
- Day 57–364 · 3 mg 3 mg, a step for more glucose control
- Day 85–364 · 4.5 mg 4.5 mg, the top dose
- Day 365+ A long-term medicine, not a course

[Every card for dulaglutide, with its sources](https://pepvault.app/peptides/dulaglutide#weeks)

## With this comparison

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Dulaglutide

- [Dulaglutide: the full reference](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)
- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks](https://pepvault.app/research/dulaglutide-surpass-j-mono-2022)
- [All 7 studies](https://pepvault.app/research#dulaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)

## Questions people ask

### How long do tirzepatide and dulaglutide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of dulaglutide is ~5 days (FDA label).

### How often are tirzepatide and dulaglutide taken?

Tirzepatide: weekly. Route: SubQ injection. Dulaglutide: weekly. Route: SubQ injection.

### How are tirzepatide and dulaglutide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The FDA label range for dulaglutide is 0.75–4.5 mg, with a 0.75 mg starting dose.

### What are the common side effects of tirzepatide and dulaglutide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For dulaglutide: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue.

## Each one in full

- [Tirzepatide: dosage, half-life & reference guide](https://pepvault.app/peptides/tirzepatide)
- [Dulaglutide: dosage, half-life & reference guide](https://pepvault.app/peptides/dulaglutide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Dulaglutide

- [Dulaglutide: the full reference](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)
- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks](https://pepvault.app/research/dulaglutide-surpass-j-mono-2022)
- [All 7 studies](https://pepvault.app/research#dulaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)

<!--promo-->

PepVault for iPhone

## Taking tirzepatide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
